APA (7th ed.) Citation

TT, D., DR, A., BR, K., BT, L., A, M., JL, W., . . . AH, B. (2020). Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PloS one, 15(3), e0230306. https://doi.org/10.1371/journal.pone.0230306

Chicago Style (17th ed.) Citation

TT, DeLeon, et al. "Assessment of Clinical Outcomes with Immune Checkpoint Inhibitor Therapy in Melanoma Patients with CDKN2A and TP53 Pathogenic Mutations." PloS One 15, no. 3 (2020): e0230306. https://doi.org/10.1371/journal.pone.0230306.

MLA (9th ed.) Citation

TT, DeLeon, et al. "Assessment of Clinical Outcomes with Immune Checkpoint Inhibitor Therapy in Melanoma Patients with CDKN2A and TP53 Pathogenic Mutations." PloS One, vol. 15, no. 3, 2020, p. e0230306, https://doi.org/10.1371/journal.pone.0230306.